Today Laboratorios Saval applied to the Public Health Institute (ISP) the emergency registry for the import and distribution in Chile of the coronavirus vaccine from the CanSino Biologics Laboratory.
According to preliminary results of CanSino’s Phase III vaccine, it achieved the pre-specified goal of primary safety and efficacy, showing 91% efficacy in preventing severe cases and 65% in preventing symptomatic cases of Covid-19.
Unlike the other vaccines that are already being applied in Chile – Pfizer, Sinovac, and soon AstraZeneca – the CanSino vaccine requires only one dose, and unlike that of Pfizer, It only needs a refrigeration between 2 and 8 ° C.
In this regard, the Minister of Sciences, Andrés Couve referred to this request for authorization, indicating that “more details will be available in the coming days.”
“We will be attentive to the ISP authorization process ”, he indicated. “This is a special vaccine, since like Sinovac, it is a vaccine that is doing clinical trials in our country”.
Recently the vaccine CanSino was approved by the Federal Commission for the Protection of Sanitary Risks (Cofepris) of Mexico for people over 18 years of age and its application is expected to begin within the next few days.
If approved for use in our country, Laboratorios Saval – who reached an agreement with the Chinese laboratory – would be in charge of importing and distributing these vaccines in Chile.
Phase 3 studies of the CanSino vaccine were conducted in Mexico, Argentina, Pakistan, Russia, Saudi Arabia, and Chile. In our country the studies were carried out by the University of La Frontera in conjunction with the Austral and San Sebastián Universities, in addition to research centers in the cities of Santiago, Temuco, Valdivia, Osorno and Puerto Montt, encompassing 3,500 volunteers.
–
